1. Home
  2. AUTL vs BWAY Comparison

AUTL vs BWAY Comparison

Compare AUTL & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

HOLD

Current Price

$1.60

Market Cap

596.2M

Sector

Health Care

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

SELL

Current Price

$11.43

Market Cap

547.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
AUTL
BWAY
Founded
2014
2003
Country
United Kingdom
Israel
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
596.2M
547.7M
IPO Year
2025
2011

Fundamental Metrics

Financial Performance
Metric
AUTL
BWAY
Price
$1.60
$11.43
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
3
Target Price
$8.73
★ $19.27
AVG Volume (30 Days)
★ 1.5M
102.6K
Earning Date
11-11-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $10,120,000.00
N/A
Revenue This Year
$98.68
$32.42
Revenue Next Year
$28.47
$23.40
P/E Ratio
★ N/A
$81.98
Revenue Growth
★ 496.00
N/A
52 Week Low
$1.18
$11.34
52 Week High
$2.58
$26.63

Technical Indicators

Market Signals
Indicator
AUTL
BWAY
Relative Strength Index (RSI) 35.87 33.15
Support Level $1.37 N/A
Resistance Level $1.73 $14.71
Average True Range (ATR) 0.09 0.49
MACD -0.01 -0.02
Stochastic Oscillator 6.41 3.20

Price Performance

Historical Comparison
AUTL
BWAY

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: